News

The companies said that the new collaboration will support the development program of therapies that caters to multiple rare diseases such as, lysosomal storage diseases (LSDs). Synageva R&D

Actemra includes labeling for inhibition and slowing of structural joint damage, improvement of physical function, and achievement of major clinical response in adult with moderately to severely active

The grant which is awarded under the Qualifying Therapeutic Discovery Project Program (QTDP) to Neogenix is totaled up to $733,437.74. The company’s NPC-1C (Ensituximab) monoclonal antibody is currently

GOLD provides evidence-based guidelines for COPD management and is updated annually by a committee of leading COPD experts. A section on the new class, phosphodiesterase 4 (PDE4) inhibitors,

The trial is designed to assess the efficacy of TriRima administered twice daily as monotherapy in patients with treatment resistant depression. CeNeRx chief medical officer Daniel Burch said

Initial results from the collaboration showed positive results in using RXi’s proprietary self-delivering rxRNA (sd-rxRNA) compounds to silence genes up to 80% in hemopoietic cells. The companies said

Rivaroxaban is an oral direct Factor Xa inhibitor, which is being jointly developed by Bayer HealthCare and Johnson & Johnson Pharmaceutical Research & Development, LLC (J&JPRD). The submission

The trial will evaluate the efficacy of Erbitux in combination with cisplatin and capecitabine chemotherapies as a first line treatment for patients with advanced/metastatic gastric adenocarcinoma, including gastroesophageal

StayinFront claims that StayinFront EdgeRx, a multi-lingual on-demand CRM with integrated analytic capabilities, offers flexibility to access the syatem online or offline featuring. Archimedes Pharma Global CIO Demi